

BTO-1 biochemical

BTO-1

CATALOG #
AAA228694


PRODUCT SYNONYMS

BTO-1; d(CH2)5Tyr(Et)VAVP; BTO-1 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	40647-02-7
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	BTO-1 (50 uM; 4 hours; U2OS cells) results in monopolar spindles in a comparable fraction of mitotic cells. BTO-1(20 uM; 1 hour; PTK cells) shows a dose-dependent reduction in phospho-Cdc25C. BTO-1(25 uM; 1 hour; PTK cells) shows about 20 % reduction in H3 phosphorylation compared to control cells. BTO-1 in HeLa cells results in a blockage of Rho and Rho-GEF recruitment, which is essential for the assembly of a functional contractile ring[1][2].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
SKF 100398, CAS 77453-01-1



Structure
SKF 100398, CAS 77453-01-1

ADDITIONAL INFORMATION

Related Product Information for BTO-1 biochemical	BTO-1 is a Polo-like kinase (Plk) inhibitor. BTO-1 is primarily used for phosphorylation and dephosphorylation applications.
References	1. S Ishikawa, et al. Further in vivo evidence for antagonist-to-antidiuretic action of arginine vasopressin. Am J Physiol. 1983 Nov;245(5 Pt 1):R713-9.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/biochemical/bto-1/228694>